Our Vision:

In this week’s blog, learn more about the latest clinical guidelines in myeloma, including the European Myeloma Network (EMN) Group consensus statement on the use of next-generation sequencing (NGS) for prognostic stratification for newly diagnosed patients. Read the New England Journal of Medicine published review, authored by IMF Chairperson of the Board Dr. S. Vincent Rajkumar and IMF Scientific Advisory Board Member Dr. Shaji Kumar, on monoclonal gammopathy of undetermined significance (MGUS), as well as a paradigm-changing paper on MGUS and smoldering myeloma, published in the Journal of Clinical Oncology. Additionally, catch up on some updates in clinical trials — including the results of the randomized phase 3 AMN003 study, published in Blood Cancer Journal. Finally, the U.S. FDA has approved GSK’s Blenrep® (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of relapsed/refractory multiple myeloma. READ THE BLOG.

“It takes a village to fight cancer!” says Dr. Cristina Gasparetto, myeloma clinician and 2025 lead cyclist of the Iceland Cycling Expedition. Be part of that village in 2026 as you ride across Iceland’s rugged terrain to raise funds for the IMF’s mission. This once-in-a-lifetime journey brings together patients, care partners, families, and professionals connected to myeloma. Only 20 spots are available, and applicants must complete a short interview. Applications are due November 20, 2025. Ready to take on the challenge? Click the link to apply, or contact the IMF Development team at [email protected] for more information. APPLY NOW.

On Thursday, October 23, 2025, the U.S. Food and Drug Administration (FDA) announced its approval of Blenrep® (belantamab mafodotin-blmf)— "a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate — with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent."

The approval is supported by data from the DREAMM-7 phase III trial. Read the news article to learn more. READ THE ARTICLE. 

The Fall 2025 edition of Myeloma Today celebrates the International Myeloma Foundation's remarkable 35-year journey of defying boundaries and redefining possibilities in the fight against myeloma. This milestone issue welcomes new President & CEO Heather Cooper Ortner, highlights groundbreaking research updates from the 2025 International Myeloma Society meeting, and showcases the 2025 Brian D. Novis Research Grant recipients. Featured content includes insights from the 21st IMF Nurse Leadership Board meeting, the 5th Asian Myeloma Network Master Class, and the inspiring 26th Annual Support Group Leaders Summit. This edition also covers crucial advocacy efforts, including Blood Cancer Awareness Month's #kNOwMyeloma campaign, the inaugural IMF Hill Day, and the transformative 2025 Iceland Cycling Expedition, while honoring the extraordinary legacy of longtime IMF Board Member Benson Klein. DOWNLOAD NOW. 

Join the IMF Virtual Myeloma Community Workshop on Monday, November 17, at 3:00 p.m. PST | 4:00 p.m. MT | 5:00 p.m. CT | 6:00 p.m. p.m. EST for expert debates on key issues in myeloma care. Hear from IMF Vice President of Patient Support Robin Tuohy and top myeloma specialists as they discuss topics like treating high-risk smoldering myeloma, using MRD to guide therapy, and CAR T-cell treatment at first relapse. The program concludes with a live panel Q&A where attendees can ask their questions directly to the experts. REGISTER NOW.

The International Myeloma Foundation (IMF) is excited to announce that an in-person Myeloma Community Workshop will take place on Saturday, November 15, 2025, at the Sheraton Raleigh (421 South Salisbury Street, Raleigh, NC 27601). Visit the following link to see which myeloma experts will present at this event: LEARN MORE.